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Glossary 
MCU        Mitochondrial calcium uniporter 
MICU1      Mitochondrial calcium uptake 1 (formerly EFHA3, CBARA1) 
MICU2      Mitochondrial calcium uptake 2 (formerly EFHA1) 
MICU3      Mitochondrial calcium uptake 3 (formerly EFHA2) 
EMRE       Essential MCU regulator 
IP        Immunoprecipitation 
siRNA       Small interfering RNA 
shRNA      Short hairpin RNA 
SDS-PAGE      Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
BN-PAGE      Blue native polyacrylamide gel electrophoresis 
PBS        Phosphate buffered saline  
DMEM      Dulbecco’s modified eagle medium 
IVT        In vitro translation 
EGTA       Ethylene glycol tetraacetic acid 
CCCP       Carbonyl cyanide m-chlorophenyl hydrazone 
TMRM      Tetramethyl rhodamine methyl ester       
CG5N       Calcium Green-5N 
ATP        Adenosine Triphosphate 
Ru-360      Ruthenium 360 
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Abstract 
The  mitochondrion  is  a  double-membrane  bound  organelle  present  in  all 
eukaryotes.  The  descendant  of  an  ancient  bacterial  ancestor,  it  has  evolved  a  vast 
number of roles in eukaryotes, including ATP production, fatty acid oxidation, steroid 
synthesis and apoptosis. Interestingly, mitochondria from a diverse set of organisms 
have the ability to transport large amounts of calcium, an essential signaling molecule in 
the  eukaryotic  cell.  This  represents  an  important  gateway  connecting  mitochondrial 
function with the rest of the cell.  
By  buffering  cytosolic  calcium,  mitochondria  can  shape  the  magnitude  and 
duration  of  intracellular  calcium  transients,  which  in  turn  govern  key  physiological 
events, including neurotransmission, oscillatory hormone release and cell differentiation. 
Although  controlled  uptake  of  calcium  into  the  matrix  influences  the  rate  of  ATP 
production, excess calcium within the matrix triggers non-specific permeabilization of 
the mitochondrial inner membrane, resulting in cell death. Consequently, mitochondrial 
calcium transport is thought to be essential in mediating life and death decisions in the 
eukaryotic cell. 
Despite  its  importance  in  cellular  physiology,  the  molecular  identity  of  the 
mitochondrial calcium uniporter remained a mystery for nearly five decades. Recently, 
an  approach  inspired  by  comparative  genomics  was  used  to  identify  two  proteins 
required for high-capacity mitochondrial calcium uptake. These include MICU1, an EF-
hand  protein  that  may  function  as  a  regulatory  component  by  sensing  calcium,  and 
MCU, the channel-forming subunit of the uniporter. Moving forward, it will be important 
to  elucidate  how  these  proteins  function  in  concert  to  achieve  high-capacity 
mitochondrial calcium uptake.    5!
In this work, I explore two distinct areas within the growing field of molecular 
mitochondrial calcium biology. First, I discuss the identification of a new protein, MICU1-
paralog EFHA1, and present data that implicates it in mitochondrial calcium uptake. 
Subsequently,  I  describe  efforts  to  establish  an  in  vitro  system  to  characterize  the 
channel activity of MCU, including my contribution to the development of a liposome-
based assay for calcium transport and preliminary work aimed at reconstituting MCU 
transport activity in proteoliposomes.  
Impaired mitochondrial calcium transport has been linked to the pathogenesis of 
cancer, neurodegeneration and ischemic injury. The therapeutic potential of targeting 
this  pathway  is  promising,  but  further  experiments  are  needed  to  clarify  the  role  of 
mitochondrial  calcium  transport  in  cellular  physiology  and  disease.  The  molecular 
characterization of the uniporter offers a diverse set of genetic approaches to tackle this 
question and opens the possibility of targeting components of the uniporter in human 
disease. 
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Introduction 
The mitochondrion is a double-membrane bound organelle located in the cytosol 
of  all  nucleated  eukaryotic  cells.  Derived  from  an  α-proteobacteria  ancestor
1,  the 
mitochondrion  is  a  fundamental  component  of  the  modern  eukaryotic  organism. 
Although the mitochondrion retains a distinct genome encoding 13 proteins on a single, 
circular chromosome, the vast majority of mitochondrial proteins are encoded in the 
nuclear genome
2, which highlights the extensive integration of this unique organelle into 
the eukaryotic cell.  
Throughout evolution, the mitochondrion has emerged as the primary site of ATP 
production,  which  is  essential  for  ion  homeostasis,  metabolic  regulation  and  cellular 
division. Within mitochondria, numerous enzymes work in concert to facilitate oxidative 
phosphorylation. This process involves coupling the oxidation of high-energy electron 
donors to the generation of a proton gradient across the mitochondrial inner membrane, 
which in turn drives ATP production via ATP synthase
3. In addition to generating cellular 
energy,  mitochondria  have  essential  roles  in  a  diverse  set  of  cellular  processes, 
including fatty acid oxidation, heme synthesis, steroid synthesis and apoptosis
4-7. 
  An important gateway that connects mitochondria with the cell is mitochondrial 
calcium  uptake.  The  capacity  of  mitochondria  to  buffer  cytosolic  calcium  enables 
mitochondria to shape the magnitude and duration of intracellular calcium transients, 
which in turn govern key physiological events, including neurotransmission, oscillatory 
hormone  release  and  cell  differentiation
8-10.  Within  the  mitochondrial  matrix,  calcium 
activates several dehydrogenases that produce high-energy electron donors that are 
substrates  for  oxidative  phosphorylation
11.  This  regulatory  mechanism  enables 
mitochondrial calcium uptake to alter oxidative metabolism
12. Although controlled uptake   7!
of calcium into the matrix influences the rate of ATP production, excess calcium within 
the matrix triggers non-specific permeabilization of the mitochondrial inner membrane, 
resulting  in  cell  death
7,13.  Therefore,  mitochondrial  calcium  uptake  is  an  important 
regulatory point that enables mitochondria to coordinate a diverse set of cellular events 
with ATP production. 
The phenomenon of mitochondrial calcium uptake was discovered over 50 years 
ago in isolated rat mitochondria
14,15. These landmark experiments showed that isolated 
mitochondria  have  the  capacity  to  take  up  large  amounts  of  calcium  present  in  the 
buffer.  Follow  up  studies  revealed  that  this  transport  activity  was  present  in 
mitochondria  isolated  from  a  diverse  set  of  organisms,  including  chicken,  turtle  and 
Neurospora  crassa
16.  The  biophysical  properties  of  this  high-capacity  uptake 
mechanism  were  described  extensively  in  subsequent  work.  These  experiments 
demonstrated that the uptake mechanism was dependent on mitochondrial membrane 
potential,  allosterically  activated  by  calcium  and  sensitive  to  ruthenium  red
15,17,18. 
Furthermore,  mitochondrial  calcium  uptake  was  not  coupled  to  another  ion,  thereby 
establishing  it  as  a  high-capacity  uniporter  mechanism
19,20.  These  findings  were 
extended  to  intact  cells  following  the  development  of  genetically  encoded  calcium 
indicators  that  could  be  targeted  to  the  mitochondria
21.  Patch  clamp  studies  further 
corroborated these findings by providing evidence that the uniporter mechanism is due 
to a highly selective ion channel
22. Despite its central importance in cellular physiology, 
the molecular identity of the mitochondrial calcium uniporter remained a mystery for 
nearly fiver decades, eluding attempts to purify it from mitochondria isolated from a wide 
array of animal tissues
23,24.   8!
  Recently, the Mootha lab pioneered a novel approach to identify components of 
the  mitochondrial  calcium  uniporter
25,26.  The  observation  that  uniporter  activity  is 
present  in  vertebrates  and  kinetoplastids,  yet  absent  in  Saccharomyces  cerevisiae 
motivated  a  computational  strategy  to  prioritize  genes  that  match  this  evolutionary 
profile and localize to the mitochondria. These criteria generated a list of 58 candidate 
genes. When a subset of these candidates were screened using a loss-of-function cell-
based assay, MICU1, a poorly studied gene containing EF-hands, was identified as a 
putative regulatory subunit of the mitochondrial calcium uniporter
25. In a follow-up study, 
MICU1 was used as “computational bait” to identify genes with a similar evolutionary 
signature and expression pattern across different tissues. This led to the discovery of a 
novel transmembrane protein, named MCU, which encodes the elusive pore-forming 
subunit of the mitochondrial calcium uniporter
26.   
In this thesis, I present two bodies of work, each which explores a distinct area 
within the growing field of molecular mitochondrial calcium biology. First, I discuss the 
identification of a new gene, MICU1-paralog EFHA1, now called MICU2, and present 
data that implicates this protein in mitochondrial calcium uptake. Secondly, I discuss my 
contribution  to  establishing  a  system  to  characterize  the  channel  activity  of  MCU, 
including the development of a liposome transport assay for calcium, and preliminary 
work in proteoliposome reconstitution of MCU. 
Since  completion  of  this  work,  a  number  of  important  studies  have  been 
published which shed light on how MCU, MICU1 and MICU2 interact to coordinate high 
capacity mitochondrial calcium transport. In the initial characterization of MICU1, there 
was a striking defect in the rise of mitochondrial free calcium in response to agonist 
stimulation
25, suggesting that calcium conductance via the uniporter was decreased,   9!
though reduced uniporter conductance was not formally demonstrated. This profound 
defect was also observed in cells expressing exogenous MICU1 with mutated EF-hands 
on a knockdown background, pointing to the critical function of MICU1’s EF-hands in 
mediating high-capacity mitochondrial calcium uptake. At this time, it was postulated 
that MICU1 likely functions as either 1) a calcium buffer with a secondary impact on 
calcium transport or 2) a calcium sensor that directly interacts with a channel protein to 
impart  allosteric  regulation  of  calcium  transport  across  the  inner  mitochondrial 
membrane
25. Since this discovery, a number of studies have clarified that MICU1 in fact 
has two critical roles in regulating mitochondrial calcium transport. First, it acts as a 
gatekeeper to keep MCU closed at low cytosolic calcium concentrations (<500 nM)
27-29, 
and secondly, it imparts cooperativity to MCU via its EF-hands, thereby enabling high 
capacity uptake in response to abrupt rises in cytosolic calcium
27,29. Although there has 
been controversy in whether MICU1 imparts cooperativity to MCU transport, multiple 
studies  have  confirmed  that  MICU1  is  indeed  a  co-factor  necessary  for  cooperative 
calcium uptake at high calcium concentrations
27,29. The discrepancy in whether MICU1 
imparts cooperativity to MCU transport likely stems from the absence of physiological 
magnesium in the transport assay used by Mallilankaraman et al. given that magnesium 
has previously been shown to be a necessary co-factor for allosteric regulation of the 
uniporter. In light of these new studies, the significantly blunted rise in free mitochondrial 
matrix calcium in response to agonist stimulation in MICU1 knockdown cells was likely 
due to a combination of reduced MCU expression, altered matrix buffering and altered 
matrix pH rather than a dramatic decrease in calcium conductance. 
In addition to a deeper understanding of MICU1, recent studies have confirmed 
that MCU is indeed the pore-forming subunit that enables calcium transport across the   10!
mitochondrial inner membrane. Perhaps, the most definitive evidence in support of this 
function  is  data  from  voltage-clamping  mitoplasts  (vesicles  composed  of  inner 
mitochondrial  membrane)  measuring  uniporter  current  in  the  setting  of  altered  MCU 
expression
30. These experiments unequivocally demonstrated that knockdown of MCU 
abrogates uniporter current, overexpression of MCU increases current and that a point 
mutation in the pore domain abolishes sensitivity to Ruthenium 360, the most specific 
inhibitor of uniporter current. Interestingly, MCU has a paralog which has been named 
MCUb (CCDC109b) that has ~50% sequence similarity to MCU
31. Of note, the protein 
sequence  harbors  mutations  in  the  predicted  pore  domain  and  exerts  a  dominant 
negative effect in cell culture and planar lipid bilayer experiments, which may represent 
an additional mechanism of control over mitochondrial calcium transport. 
Within the past few months, an additional component of the uniporter complex 
was identified using mass spectrometry. This protein, EMRE, is required for uniporter 
channel activity
32. In addition, it is required for the interaction between MCU and MICU1, 
suggesting that it bridges the calcium-sensing role of MICU1 with the channel activity of 
MCU. In this study and others, MICU1 and MICU2 are within the intermembrane space, 
though this remains a subject of ongoing debate
32.  At present, the current data points 
to a model in which MCU forms a high capacity calcium channel that is inhibited under 
low calcium concentrations by MICU1 and MICU2, which release their inhibitory effects 
at higher calcium concentration via calcium binding to their EF-hands. 
Several  studies  have  implicated  mitochondrial  calcium  uptake  in  the 
pathogenesis of cancer, neurodegeneration and ischemic injury
7,33-36. A recent study 
reports the first mutation in MICU1 in an individual with progressive myopathy, learning 
difficulties  and  a  progressive  extrapyramidal  movement  disorder,  underscoring  the   11!
importance of mitochondrial calcium handling in human disease
37. Much like the results 
in cell culture, fibroblasts isolated from this individual demonstrated increased calcium 
transport  at  low  cytosolic  calcium  concentrations  in  the  setting  of  mutated  MICU1, 
further solidifying the role of MICU1 as a negative regulator of uniporter activity at low 
calcium concentrations
37. In a study describing the first MCU knockout mouse, there 
was  impaired  activity  of  pyruvate  dehydrogenase,  a  mitochondrial  calcium-activated 
enzyme,  in  skeletal  muscle  in  mice  lacking  MCU  expression
38.  The  most  striking 
phenotype in this study was the impaired ability of MCU null mice to perform strenuous 
work.  Despite  the  exciting  therapeutic  potential  raised  by  these  findings,  the  role  of 
mitochondrial calcium transport in cellular physiology and disease has yet to be fully 
explored. The molecular characterization of the uniporter and its regulators represents a 
major advance towards this goal and opens up the possibility of targeting components 
of the uniporter for the treatment or prevention of disease. 
!
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Chapter 1: MICU2 is a paralog of MICU1 that partners with the uniporter to control 
mitochondrial calcium uptake 
 
INTRODUCTION 
Recently, a novel approach coupling insights from comparative physiology and 
integrative genomics led to the identification of two proteins required for high-capacity 
mitochondrial calcium uptake, which include MICU1
25 and MCU
26. Based on sequence 
analysis  and  functional  studies,  we  hypothesized  that  MCU  is  the  channel-forming 
subunit of the uniporter, whereas MICU1 is a key regulatory component that senses 
calcium  via  its  EF  hands.  This  model  has  been  corroborated  by  independent  and 
complementary studies
39 which suggest that MICU1 inhibits MCU at resting cytosolic 
calcium concentrations and triggers allosteric activation of the channel at  high cytosolic 
concentrations. 
Interestingly,  genome  sequence  analysis  reveals  that  MICU1  has  two  human 
homologs,  EFHA1 a n d  EFHA2,  neither  of  which  has  been  studied.    Both  of  these 
proteins  have  mitochondrial  targeting  sequences  and  were  previously  identified  with 
high  and  low  confidence,  respectively,  in  MitoCarta,  a  proteomic  characterization  of 
mitochondria from 14 different mouse tissues
2.  In this work, we sought to determine 
whether EFHA1 is also critical for mitochondrial calcium uptake. Decades of research 
have shown that uniporter activity exists in all vertebrate tissues, but that its regulation 
is  distinct
16,40.  It  is  possible  that  the  presence  of  multiple  regulatory  proteins  could 
provide  a  molecular  explanation  for  tissue  specific  regulation  of  the  mitochondrial 
calcium uniporter. 
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MATERIALS AND METHODS 
Multiple sequence alignment 
Sequences were downloaded from the NCBI protein database. ClustalW2 was used to 
multiple sequence alignment and generate a phylogenetic tree. 
 
Cell Culture 
HeLa  and  HEK293T  cells  were  received  from  the  ATCC.  HeLa  cells  expressing 
aequorin  targeted  to  the  mitochondrial  matrix  (mt-AEQ)  were  purchased  from 
Aequotech (AT-002-H). Cells were grown at 37°C and 5% CO2 in Dulbecco’s modified 
Eagle medium (DMEM) (Invitrogen 11995) with 10% FBS (Sigma F6178). HeLa cells 
expressing mt-AEQ were cultured in 100 µg/ml of geneticin. 
 
Confocal imaging 
HeLa  cells  were  transfected  with  plasmids  containing  carboxy  terminus  GFP-tagged 
MICU2 or Mito-HcRed1 (Clontech 632434). Twenty-four hours after transfection, cells 
were  washed  three  times  with  PBS,  then  imaged  using  a  Leica  TCS  SP5  confocal 
microscope. 
 
Immunoprecipitation 
Mitochondria were isolated from HEK-293T cells that stably express Flag-tagged GFP 
targeted to mitochondria or MCU-Flag. 200 µg of protein were solubilized using 200 µl 
of lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.2% DDM and 
protease inhibitor tablets (Roche Applied Science 118361170001)) for 10 minutes at 4 
°C. Lysates were cleared by spinning at 16000g for 10 minutes at 4 °C. Cleared lysates   14!
were incubated with 10 µl of anti-Flag M2 affinity gel (Sigma A2220) in PBS for 2 hours 
at 4 °C. Immunoprecipitates were washed with 1 ml of lysis buffer 3 times, and boiled in 
30 µl of sample buffer. A third of the immunoprecipitate was loaded on a 12% SDS-
PAGE  gel  for  detection  of  the  indicated  proteins.  MCU  antibody  was  generated  in 
chicken, MICU1 antibody was generated in rabbit and MICU2 antibody was purchased 
from Abcam (ab101465). 
 
Synthesis and selection of siRNA duplexes targeting MICU1 and MICU2 
48 and 20 siRNAs were selected for synthesis and screening based on low-predicted 
off-target  potentials  and  100%  homology  with  mouse  sequences  NM_144822.2  and 
NM_028643.3,  respectively.  Single-strand  RNAs  were  produced  at  Alnylam 
Pharmaceuticals as previously described
41. Hepa-1c1c7 cells seeded at 15,000 cells 
per well in 96-well plates were transfected with siRNAs using Lipofectamine RNAiMAX 
according to the manufacturer's protocols. Each experiment was performed in technical 
duplicate. 18-24h post-transfection, MICU1 and MICU2 mRNA levels were quantified 
using a branched-DNA assay (QuantiGene Reagent System, Panomics) according to 
the manufacturer's protocols. Their mRNA levels were normalized to GAPDH mRNA. 
 
In vivo silencing of MICU1 and MICU2 
All procedures used in animal studies were approved by the Institutional Animal Care 
and Use Committee. C57BL/6 mice (Charles River Laboratories) received either PBS or 
siRNA in lipidoid formulations via weekly tail vein injections as previously described
26,42-
44. After overnight fasting, the animals were euthanized by CO2 inhalation and the livers   15!
were harvested and stored in ice-cold PBS prior to mitochondria isolation. A piece of 
liver tissue was snap-frozen in liquid nitrogen for mRNA analysis. 
 
Mitochondrial Isolation 
Mitochondria  were  isolated  from  mouse  liver  as  previously  described
45 a n d  
resuspended in a buffer containing 220 mM mannitol, 75 mM sucrose, 10 mM HEPES 
and 1 mM EDTA, adjusted to pH 7.4 with KOH, and supplemented with fresh 0.2% BSA 
prior to use. Mitochondria were stored on ice until further use. 
 
Measurement  of  mitochondrial  respiration  and  membrane  potential  in  isolated 
mitochondria 
Respiration and membrane potential were measured optically as previously described
45. 
Values for respiratory control ratios (RCR) and ADP:O (P:O) ratios represent the mean 
+/- s.d. of three independent experiments performed on n=3 mice.  
 
Measurement of mitochondrial calcium uptake in isolated mitochondria 
Calcium  uptake  was  performed  on  a  Perkin-Elmer  Envision  plate  reader  and  Perkin 
Elmer LS-50B fluorescence spectrometer as previously described
26. Inset reports linear 
fits between 5 and 10s from experiments performed on n=3 mice. 
 
RNA interference 
To silence MICU1, we used short-hairpin RNA (shRNA) constructs (TRCN0000053370, 
5’-GCAATGGCGAACTGAGCAATA-3’,  sh-MICU1a a n d  TRCN0000053368,  5’-
GCAGCTCAAGAAGCACTTCAA-3’,  sh-MICU1b)  from  the  Broad  Institute’s  RNAi   16!
Consortium  (TRC)  previously v a l i d a t e d  i n  m t -AEQ  HeLa  cells.  As  controls,  shRNAs 
targeting GFP, RFP and LACZ were used. All shRNAs were provided in a lentiviral 
vector (pLKO.1) through the TRC. Lentiviral production and infection was performed as 
previously  described
46.  Cells  were  selected  24  hours  after  infection  with  2  mg/ml  of 
puromycin.  
 
cDNA rescue experiments 
A lentiviral vector (pLEX983) for expressing C-terminal V5-tagged cDNA was obtained 
from the TRC. Full-length MICU2 cDNA was synthesized (Blue Heron Biotechnology) 
and cloned into pLEX983. Lentivirus was produced using cDNAs encoding GFP, MICU2 
or MICU1 resistant to TRCN0000053370 as previously described
46. Virus was used to 
infect HeLa cells stably expressing mt-AEQ. Cells were selected 24 hours after infection 
with 5 µg/ml of blasticidin.  
 
Measurement of mitochondrial calcium in HeLa cells expressing mt-AEQ 
40,000  cells  were  seeded  in  a  96-well  plate,  incubated  overnight  with  mitochondrial 
calcium  measured  following  histamine  treatment  as  previously  described
47.  Light 
emission  was  measured  at  469  nm  every  0.1s  using  a  luminometer  (MicroBeta
2 
LumiJET  Microplate  Counter  PerkinElmer).  Subsequently,  luminescence  was 
normalized to account for cell number. 
 
Blue native PAGE studies 
5 µg of mitochondria isolated from mouse liver or HeLa cells were solubilized in 2% 
digitonin  on  ice  for  30  minutes.  Electrophoresis  was  performed  using  the  Novex   17!
NativePAGE Bis-Tris Gel System from Invitrogen. Western blot analysis was performed 
using  an  MCU  antibody  generated  in  chicken.  A  commercially  available  antibody  to 
ATP5A1 (MitoSciences MS507) was used as a loading control. 
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RESULTS 
MICU1, MICU2, and MICU3 form a family of paralogs 
In  previous  work,  we  used  comparative  genomics  to  identify  MICU1,  a 
mitochondrial  protein  essential  for  normal  mitochondrial  calcium  handling i n  H e L a  
cells
25.  MICU1,  previously  known  as  CBARA1  or  as  EFHA3,  has  a  mitochondrial 
targeting  sequence  as  well  as  two  evolutionarily  conserved  EF  hands.    Genome 
sequence analysis reveals that MICU1 shares significant sequence similarity with two 
human genes, EFHA1 and EFHA2, neither of which has been studied before. These 
three proteins are conserved in vertebrates, whereas only one homolog is present in 
plants and protozoa. 
I  performed  a  multiple  sequence  alignment  using  homologs  from  vertebrates, 
plants and protozoa which placed the protozoa and plant homologs as outgroups on a 
phylogenetic tree (Figure 1a), thereby indicating that EFHA1 and EFHA2 are vertebrate 
paralogs of MICU1 that likely arose from a gene duplication event prior to vertebrate 
evolution.  Based on this finding, we have re-named EFHA1 as MICU2, and EFHA2 as 
MICU3. 
  MICU2 a n d  MICU3 h a v e  N -terminal  targeting  sequences  consistent  with 
mitochondrial  localization,  much  like  MICU1  (22).  In  our  previous  proteomic  studies, 
MICU2 and MICU3 were detected in mitochondria from various mouse tissues, although 
their expression patterns differed significantly (16).  MICU1 was broadly expressed and 
detected in 12 out of 14 mouse tissues, whereas MICU2 was detected in 7 out of 14 
tissues with strong expression in visceral organs. In contrast, MICU3 was found in 6 out 
of 14 tissues with a strong signature in skeletal muscle and the central nervous system.  
Despite  being  detected  in  multiple  mouse  tissues,  MICU3  lacked  other  evidence  of   19!
being mitochondrial, scoring just below the stringent threshold required to be a part of 
the MitoCarta collection.  This is in contrast to MICU2, which was reported in MitoCarta 
and localized to the mitochondria using high-content microscopy. 
Due to stronger evidence for mitochondrial localization and greater expression in 
visceral organs in which we can apply siRNA technology to achieve in vivo silencing, we 
decided  to  focus  on  MICU2  for  functional  studies.  Sequence  comparison  of  human 
MICU1 and MICU2 reveals highly conserved domain architecture (Figure 1b). Similar to 
MICU1, MICU2 has two EF-hands separated by a long stretch of residues predicted to 
form a helix. In previous work, we showed that the calcium-coordinating residues in the 
EF-hands  of  MICU1  are  highly  conserved  across  species
25.  Like  MICU1,  MICU2 
demonstrates perfect conservation in the acidic residues that cap the EF-hands across 
evolution (Figure 1b).  
 
MICU2 localizes exclusively to mitochondria   
First,  we  confirmed  that  MICU2  localizes  exclusively  to  mitochondria  with  confocal 
microscopy, which showed that a carboxy terminus GFP-tagged MICU2 overlapped with 
mitochondrial marker Mito-HcRed1 (Fig. 1c).   20!
 
 
Figure 1. MICU2 is paralogous to MICU1 and localizes exclusively to the mitochondrion. 
(a) MICU1, MICU2 and MICU3 share a common ancestor and are present in multiple vertebrate 
species. (b) MICU2 has two evolutionarily conserved EF hands. (c) Representative confocal 
image of HeLa cells co-transfected with MICU2-GFP and Mito-HcRed1. 
 
MICU1 and MICU2 are Cross-Stabilized at a Protein Level 
Previously,  we  demonstrated  that  MICU1  is  required  for  normal  mitochondrial 
calcium handling in HeLa cells. Given that MICU1 and 2 are paralogs with conserved 
domain architecture, they may have redundant roles and be expressed in a mutually 
exclusive  manner  across  different  cell  types.  To  address  this  possibility,  we  blotted 
whole  cell  lysate  from  HeLa  cells  for  MICU1  and  MICU2,  which  demonstrated 
expression  of  both  proteins  (Figure  2a).  Interestingly,  in  the  setting  of  MICU1 
knockdown,  there  was  a  significant  reduction  in  MICU2  expression,  suggesting  that 
A
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these  paralogs  undergo  cross-stabilization  at  a  protein  level  (Figure  2a).  This  was 
observed following treatment with multiple hairpins that specifically target MICU1 and 
not MICU2 (sh-MICU1a and sh-MICU1b), indicating that this is a biological consequence 
of MICU1 loss rather than an off target effect. 
 
MICU2 associates with the MICU1/MCU complex  
To  determine  whether  MICU2  physically  interacts  with  these  proteins,  we 
performed immunoprecipitation on cells stably expressing either MCU-FLAG or GFP-
FLAG.  Although endogenous MICU1 and MICU2 were present in cell lysate from both 
cell lines, immunoprecipitation with an anti-FLAG antibody specifically recovered MICU1 
and MICU2 from the MCU-FLAG cell line (Figure 2b). It is notable that the heterologous 
expression of MCU-FLAG resulted in increased protein expression of both MICU1 and 
MICU2, as seen in whole cell lysate (Figure 2b), suggesting that MCU overexpression 
either induces or stabilizes the expression of MICU1 and MICU2. Collectively, these 
results  demonstrate  that  MICU2  physically  interacts  with  MICU1  and  MCU,  further 
supporting a possible role for MICU2 in mitochondrial calcium uptake.    22!
 
Figure 2. MICU2 protein expression is stabilized by MICU1 and interacts with MCU and 
MICU1. (a) Whole cell lysates from HeLa cells stably expressing a control sh-RNA (sh-GFP, sh-
RFP, sh-LACZ) or a sh-RNA targeting MICU1 (sh-MICU1a and sh-MICU1b) were blotted with 
anti-MICU1, anti-MICU2 and control anti-ATP5A. (b) Mitochondria isolated from HEK293T cells 
stably expressing MCU-FLAG or GFP-Flag targeted to mitochondria were solubilized with 0.2% 
DDM  and  subjected  to  anti-FLAG  immunoprecipitation.    Immunoprecipates  and  lysate  were 
blotted with anti-FLAG, anti-MICU1, anti-MICU2 and control anti-ATP5A. 
 
MICU1 and MICU2 can be silenced in vivo in mouse liver using siRNA technology 
Together, our sequence analysis and biochemical data motivated us to pursue 
studies in which we could directly assess the contribution of MICU2 to mitochondrial 
calcium uptake. To evaluate the impact of MICU2 loss on mitochondrial calcium uptake, 
we performed in vivo silencing of MICU2 in mouse liver using technology developed by 
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Alnylam Pharmaceuticals.  We previously used this technology to report the first in vivo 
silencing of the uniporter 
26.  
A  key  question  was  whether  MICU1  and  MICU2  contribute  independently  to 
mitochondrial calcium uptake.  Therefore, we worked with collaborators at Alnylam to 
perform in vivo silencing of MICU1 in isolation and in combination with MICU2. We 
screened siRNA duplexes for both genes using previously described siRNA design and 
delivery technology
26. Duplexes were transfected at concentrations from 1.25 to 5 nM, 
and the 3 siRNAs conferring the best knockdown were tested at different concentrations 
in the range of 7 pM to 5 nM to estimate their EC50 in a mouse liver cell line (Figure 3a). 
As a negative control, we used a siRNA duplex that targets firefly luciferase (si-LUC). 
We performed a large-scale synthesis of one siRNA duplex and encapsulated it into a 
lipid-based formulation optimized for liver-specific delivery. Although mRNA knockdown 
was  achieved  at  24  hours,  weekly  tail  vein  injections  of  the  siRNA  duplexes  were 
carried out over a six-week period to achieve in vivo protein knockdown of MICU1 and 
MICU2 (Figure 3b). Similar to in vivo silencing of MCU, mice did not exhibit any signs of 
distress, their weight was stable, and the gross appearance of their livers did not differ. 
 
   24!
 
Figure  3.  MICU1 a n d  MICU2 c a n  b e  s i l e n c e d  in  vivo i n  m o u s e  l i v e r  u s i n g  s i R N A  
technology.  (a)  In  vitro  dose-response  curves  of  selected  duplexes  targeting  MICU1 a n d  
MICU2.  (b) R e l a t i v e  e x p r e s s i o n  o f  MICU1 a n d  MICU2 m R N A  a f t e r  6  w e e k l y  i n j e c t i o n s  
normalized to si-LUC mice. 
 
Mitochondrial membrane potential and respiration are intact following in vivo silencing of 
MICU1/MICU2 in mouse liver 
To begin, I evaluated the impact of silencing MICU1 and MICU2 on mitochondrial 
respiration  and  membrane  potential  (ψm)  to  ensure  that  silencing  did  not  cause 
respiratory chain collapse leading to a secondary defect in calcium uptake. Mitochondria 
isolated from control and knockdown livers underwent robust respiratory transitions as 
demonstrated  by  their  comparable  respiratory  control  ratios  (RCR)  (Figure  4a).    In 
addition,  comparable  ADP:O  ratios  indicate  intact  ATP-coupled  mitochondrial 
respiration. Together, these results indicate that silencing MICU1 or MICU2 did not alter 
mitochondrial respiration or oxidative phosphorylation.  In mitochondria isolated from all 
treatment groups, membrane potential was responsive to ADP and fully depolarized by 
the  uncoupler  carbonyl  cyanide  m-chlorophenyl  hydrazone  (CCCP),  indicating  that 
silencing MICU1 or MICU2 did not adversely affect mitochondrial membrane potential 
(Figure 4b). 
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Figure 4. Respiration and mitochondrial membrane potential are intact following in vivo 
silencing  of  MICU1 a n d  MICU2 i n  m o u s e  l i v e r .   (a)  Representative  oxygen  consumption 
traces measured in isolated mitochondria. Arrows denote addition of mitochondria, glutamate 
and malate (G/M), ADP and uncoupler (carbonyl cyanide m-chlorophenyl hydrazone, CCCP). 
Respiratory  control  ratios  (RCR)  and  ADP:O  ratios  (P:O)  were  calculated  from  experiments 
performed  on  three  separate  mice  per  group.  (b) R e p r e s e n t a t i v e  m i t o c h o n d r i a l  m e m b r a n e  
potential traces measured in isolated mitochondria using tetramethyl rhodamine methyl ester 
(TMRM). 
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In vivo silencing of MICU1 and MICU2 in mouse liver results in decreased mitochondrial 
calcium uptake.  
Next, I analyzed calcium uptake kinetics in mitochondria isolated from control 
and knockdown mice by adding a single spike of calcium to mitochondria suspended in 
buffer containing extramitochondrial Calcium Green-5N (CG5N) and observed the rate 
of calcium clearance by measuring CG5N fluorescence. Mitochondria from si-MICU1 
and si-MICU2 mice demonstrated moderately impaired calcium uptake, whereas 
mitochondria from si-MICU1 + si-MICU2 mice demonstrated an additive defect (Figure 
5a). This result was also observed when multiple spikes of calcium were added to 
mitochondria (Figure 5b). Interestingly, mitochondria from control and knockdown 
groups were able to clear the first spike of calcium, but differed significantly in their 
ability to clear a second pulse. This defect was additive in mitochondria from si-MICU1 + 
si-MICU2, which demonstrated a near complete loss of buffering in response to the 
second calcium pulse. In addition, MCU protein expression was significantly decreased 
in knockdown mitochondria (Figure 5c). The degree of MCU protein loss correlated with 
the phenotype strength, raising the question of whether MCU loss was responsible for 
at least part of the observed phenotype. Similar to the effect of MICU2 knockdown in 
HeLa cells, loss of MICU2 resulted in significantly reduced MICU1 expression. 
   27!
 
 
Figure 5. Silencing MICU1 and MICU2 in mouse liver results in impaired calcium uptake. 
(a) Calcium uptake in energized liver mitochondria following the addition of 50 mM CaCl2. Inset 
reports linear fits of uptake between 5 and 10s normalized to si-LUC uptake. (b) Calcium uptake 
in energized liver mitochondria following the addition of multiple spikes of 50 mM CaCl2. (c) 
Mouse liver mitochondria isolated from animals treated with siLUC, siMICU1, siMICU2 or 
siMICU1+2 were blotted with anti-MICU1, anti-MCU and control anti-ATP5A.! 
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In vivo silencing of MICU1 and MICU2 alters MCU complex size 
Previous  studies  using  blue  native  polyacrylamide  gel  electrophoresis  (BN-
PAGE) and western blot (WB) have demonstrated that a complex containing MCU is 
present at approximately 480 kDa. To gain insight into how silencing these proteins may 
affect  the  uniporter  complex,  I  solubilized  control  and  knockdown  mitochondria  in 
digitonin and performed BN-PAGE and western blot analysis. Blotting with anti-MCU 
revealed a shift in MCU complex size in knockdown mitochondria relative to si-LUC 
(Figure  6a).  Interestingly,  the  degree  of  shift  correlated  with  the  severity  of  calcium 
uptake. This result was also observed in human cell lines stably expressing sh-MICU1 
and sh-LZ (Figure 6b). This could be rescued by introducing a cDNA encoding MICU1 
that  was  resistant  to  sh-RNA  degradation,  suggesting  that  this  shift  was  specific  to 
MICU1 knockdown to rather than an off-target effect (Figure 6c).   29!
 
Figure 6. Silencing MICU1 and MICU2 alters MCU complex size. (a) BN-PAGE analysis of 
mouse liver mitochondria isolated from animals treated with si-LUC, si-MICU1, si-MICU2 or si-
MICU1 and si-MICU2. Protein was transferred to a membrane and blotted for MCU and ATP5A 
(loading  control).  (b) B N -PAGE  analysis  of  mitochondria  isolated  from  HeLa  cells  stably 
expressing sh-GFP or sh-MCU. Protein was transferred to a membrane and blotted for MCU 
and ATP5A (loading control). (c) BN-PAGE analysis of mitochondria isolated from HeLa cells 
stably expressing sh-GFP and GFP, sh-MICU1 and GFP or sh-MICU1 and rMICU1, a cDNA 
encoding MICU1 with eight synonymous mutations in the sh-MICU1 target sequence. MCU and 
ATP5A (loading control) were visualized by western blot. 
 
Stable expression of MICU2 rescues a calcium uptake defect in the setting of reduced 
MICU1 
The additive defect observed in simultaneous silencing of MICU1 and MICU2 in 
mouse liver suggests that they contribute independently to establishing the capacity of 
mitochondria to buffer calcium. However, the finding that their loss results in similar 
defects,  including  reduced  calcium  uptake  and  a  shift  in  the  MCU  complex  size, 
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indicates that they may have similar or overlapping roles in mediating mitochondrial 
calcium uptake. Although MICU1 knockdown results in a profound reduction in calcium 
uptake,  it  also  significantly  reduces  MICU2  expression,  which  complicates  the 
interpretation of this phenotype and raises the question of whether MICU2 can restore 
calcium uptake in the setting of reduced MICU1 expression.  
To  pursue  this  question,  I  stably  expressed  MICU2  in  HeLa  cells  containing 
aequorin  targeted  to  the  mitochondrial  matrix  and  introduced  a  sh-RNA  targeting 
MICU1.  Subsequently,  I  evaluated  the  ability  of  this  cell  line  to  transport  calcium  in 
response to histamine stimulation. This experiment revealed that MICU2 could restore 
mitochondrial calcium uptake in the setting of significantly reduced MICU1. Interestingly, 
although  MCU  expression  was  not  decreased  by  loss  of  MICU1,  it  could  not 
compensate for MICU1 loss. This strongly suggests that MICU2 specifically rescues a 
MICU1  phenotype  either  by  stabilizing  low  levels  of  remaining  MICU1  or  directly 
compensating for MICU1 as a functional paralog.   31!
 
Figure 7. Stable expression of MICU2 rescues a calcium uptake defect in the setting of 
reduced MICU1. (a) Luminescence measurements of mitochondrial calcium following histamine 
stimulation in HeLa cells stably expressing aequorin targeted to the mitochondrial matrix (mean 
± s.e.m., n = 4). Inset reports statistics on the maximal luminescence (mean ± s.d., n = 8, *P < 
0.001). (b) Western blot analysis of cells stably expressing sh-MICU1 and GFP, sh-MICU1 and 
rMICU1, sh-MICU1 and MICU2, or sh-GFP and GFP. 
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DISCUSSION 
MICU1 represents the founding member of a family of paralogous proteins that 
includes MICU2 and MICU3, which likely arose by a gene duplication event prior to 
vertebrate  evolution.    Although  both  of  these  proteins  have  evidence  as  being 
mitochondrial,  MICU2  is  a  high  confidence  mitochondrial-localized  protein  whereas 
MICU3  is  likely  mitochondrial  but  with  lower  confidence
2.  Therefore,  MICU2  was 
prioritized for functional studies, but it is likely that MICU3 has a role in mitochondrial 
calcium uptake in a subset of tissues, notably in the neuromuscular system. In previous 
work, it was reported that loss of MICU1 in HeLa cells results in impaired mitochondrial 
calcium handling
25, but it was unclear if this property extended to other cell types.  The 
current study extends this finding to mouse liver, establishing the central role of MICU1 
in  regulating  calcium  transport  in  mammalian  mitochondria.  Our  findings  also 
demonstrate that silencing MICU1 or MICU2 in vivo in mouse liver results in moderately 
impaired mitochondrial calcium handling, whereas silencing both proteins has a more 
dramatic and perhaps additive effect.  
In the present study, we demonstrate that MCU, MICU1 and MICU2 reside within 
a  large  complex,  which  we  refer  to  as  the  uniporter  complex.  This  is  supported  by 
results  from  immunoprecipitation  studies  and  by  the  observation  that  these  protein 
undergo  cross-stabilization  at  the  protein  level  across  multiple  cell  types.  Further 
supporting  the  notion  that  they  reside  in  a  complex,  silencing  of  MICU1  or  MICU2 
results in a reduction in the MCU complex size as seen on BN-PAGE analysis. Taken 
together,  these  studies  reveal  that  MICU2  is  a  bona  fide  member  of  the  uniporter 
complex.   33!
Though  implicated  in  mitochondrial  calcium  handling,  the  exact  molecular 
functions of MICU1 and MICU2 remain unclear. Mitochondria isolated from mouse liver 
in which MICU1 and MICU2 were silenced demonstrated a markedly impaired ability to 
clear large 50 uM pulses of calcium. It is unclear if this is secondary to reduced MCU 
expression or a direct consequence of losing MICU1 and MICU2. At present, potential 
roles for MICU2 include 1) calcium sensing and regulation of MCU, 2) calcium buffering 
with a secondary impact on uniporter transport or 3) assembly and stabilization of MCU. 
Recent work suggests that MICU1 inhibits MCU at low cytosolic calcium concentrations, 
thereby  setting  the  threshold  for  mitochondrial  calcium  uptake.  In  addition,  there  is 
compelling  evidence  that  MICU1  senses  calcium  via  its  EF  hands,  which  enable  it 
disinhibit  MCU  activity  in  response  to  appropriate  spikes  in  cytosolic  calcium.  How 
MICU2 contributes to the regulation of MCU activity remains unclear.  
An important question raised by our work is whether MICU1 and MICU2 have 
redundant  or  distinct  molecular  functions  in  mitochondrial  calcium  uptake.  The 
evolutionary  conservation  of  both  paralogs  in  vertebrates,  their  distinct  patterns  of 
expression across organs and the presence of MICU1 and MICU2 in two different cell 
types point to complementary roles in cellular physiology. However, it is unclear if they 
are redundant or distinct on a molecular level. We attempted to complement a strong 
MICU1 phenotype in HeLa cells that we previously reported by expressing MICU2 on a 
MICU1 knockdown background. Although MICU2 was able to rescue this phenotype, 
we  found  that  MICU2  also  stabilized  the  protein  expression  of  the  small  amount  of 
MICU1,  confounding  the  interpretation  of  this  critical  experiment.  Resolving  this 
question will likely require the use of a null genetic background in which the activity of 
one paralog can be rigorously assessed in the absence of the other paralog. Moving   34!
forward,  it  will  also  be  important  to  consider  other  mechanisms,  including  those 
involving  MCUR1,  LETM1  and  NCLX  that  may  additionally  influence  mitochondrial 
calcium physiology
48-50.  
Decades of research have shown that uniporter activity exists in all vertebrate 
tissues, but that its regulation is distinct
16,40. It is possible that the relative expression of 
MICU1,  MICU2  and  MICU3  differ  in  a  cell  and  state-specific  manner  to  regulate 
uniporter activity. Under this model, multiple paralogs could be constitutively expressed 
in a single cell type, but variation in their relative abundance could give rise to functional 
differences in uniporter activity. If this model proves to be correct, it may enable the 
possibility of therapeutically targeting the uniporter in a tissue specific manner. 
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Chapter 2: Developing a System for Proteoliposome Reconstitution of MCU 
 
INTRODUCTION 
  Targeting  ion  channels  and  transporters  is  a  common  mechanism  of  many 
therapeutic agents
51. Drugs that alter the activity of plasma membrane channels and 
transporters include anesthetics, antiarrhythmic and antihypertensive agents. There are 
also compounds that act on intracellular channels and transporters to modulate cellular 
activity,  including  caffeine  and  dantrolene
52,53.  These  drugs  provide  a  precedent  for 
targeting MCU, the channel-forming subunit of the mitochondrial calcium uniporter.  
Although  we  showed  that  MCU  is  an  essential  component  of  the  uniporter
26, 
another group provided direct evidence that MCU is a calcium channel
39. This group 
reconstituted  purified  MCU  in  planar  lipid  bilayers  and  obtained  single  channel 
recordings consistent with uniporter activity
39. Their results appeared in a companion 
paper and complemented our in vivo results, which demonstrated that loss of MCU in 
mouse liver abolished calcium uptake. Together, these two bodies of work established 
MCU as the pore-forming subunit of the mitochondrial calcium uniporter. 
Moving forward, we would like to establish a system for large-scale reconstitution 
of MCU in proteoliposomes. In this chapter, I describe my contributions to the three 
components  of  an  in  vitro  reconstitution  system  including  establishing  an  assay  for 
transport, generating soluble protein, and incorporating it into vesicles. First, I discuss 
the development of a fluorescence-based liposome transport assay that will allow us to 
assess whether MCU proteoliposomes demonstrate biophysical properties consistent 
with the mitochondrial calcium uniporter. Subsequently, I will discuss preliminary work in 
generating soluble MCU for reconstitution into lipid vesicles. This system will allow us to 
confirm the results seen at the single-channel level and further explore the biophysical   36!
properties of the mitochondrial calcium uniporter, which will enhance our understanding 
of  mitochondrial  calcium  biology  and  motivate  further  experimental  investigation. 
Ultimately, it may also provide a platform for a high-throughput in vitro chemical screen 
to identify novel therapeutics targeting mitochondrial calcium transport, which can then 
be validated in cell-based models.  
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MATERIALS AND METHODS 
Preparation of asolectin vesicles 
Asolectin lipid purchased from Avanti Polar Lipids (541601G) was dissolved in 
chloroform at a concentration of 25 mg/ml. It was mixed with an equal volume of buffer 
A (140 mM KCl, 10mM HEPES, pH 7.0) and 1 mM EGTA and incubated at 13°C for 24 
hours. Buffer A was removed, and the asolectin chloroform solution was placed in a 
round-bottom flask and dried under a steady stream of nitrogen. The round-bottom flask 
was then placed in a dessicator overnight. The following day, asolectin was rehydrated 
in Buffer B (Buffer A + 50 µM EGTA) to a final concentration of 35 mM. The solution 
was vortexed at high speed for 2 minutes and incubated at room temperature for at 
least 4 hours with a 2-minute vortexing period every hour. The rehydrated lipid was then 
sonicated for 2 minutes using a low-power sonicator. Calcium Green-5N (CG5N) was 
added to the rehydrated lipid to a final concentration of 84 µM. The solution was taken 
through five freeze thaw cycles. The lipid was extruded 21 times using a 0.1 µm filter. 
Following extrusion, the sample was diluted to 3 ml with Buffer B and poured over an 
equilibrated desalting column to remove unincorporated CG5N. The sample was then 
eluted  in  3  ml  of  Buffer  B  for  experimental  analysis  with  a  fluorescence 
spectrophotometer. 
 
Measurement of calcium transport in asolectin vesicles 
The eluted sample was diluted in Buffer B to a final concentration of 0.2-2 mg/ml. 
Fluorescence  (Ex.  506/Em.  531nm)  was  monitored  at  room  temperature  using  a 
stopped  flow  spectrophotometer  or  a  Perkin-Elmer  LS-50B  fluorescence 
spectrophotometer  equipped  with  a  stirring  device.  Calcium  ionophore  A23187  was   38!
added  at  a  concentration  ranging  from  500  nM  to  5  µM.  This  was  followed  by  the 
addition of calcium (10 mM) or EGTA (1 mM). Experiments were performed in which the 
ionophore was added after the addition of calcium or EGTA. This scheme produced 
equivalent results. 
 
Cell-free expression of MCU 
MCU  was  cloned  into  a  vector  (pEXP5-CT/TOPO)  optimized  for  cell-free 
expression. This vector was also selected because it has a C-terminal 6xHis tag for 
affinity purification and detection by western blot. MembraneMax Protein Expression Kit 
(A10632) was purchased from Invitrogen. Protein synthesis was carried out according 
to the directions outlined in the kit manual. E. coli extract, reaction buffer, amino acids 
and DNA were combined and incubated in a thermomixer (1200 rpm) at 37°C for 30 
minutes. The reaction was then supplemented with feed buffer and amino acids and 
carried out for an additional two hours. Bacteriorhodopsin (bR) DNA was provided with 
the kit and used a positive control for protein expression.  
 
Analysis of MCU yield following cell-free expression 
To estimate total MCU production, protein was precipitated with acetone and the 
samples  were  analyzed  using  SDS-PAGE  and  western  blot.  To  determine  whether 
MCU was soluble, a portion of the reaction was spun at 20,000g for 30 minutes, and the 
supernatant  was  removed  for  acetone  precipitation  and  western  blot  analysis. 
Quantitative estimates of total and soluble protein yield were made using a cocktail of 
five His-tagged proteins (Qiagen 34705) with known concentrations. 
   39!
Supplementation of cell-free reactions with detergent or liposomes 
Cell-free  reactions  were  supplemented  with  detergent  at  the  beginning  of  the 
incubation period and the concentration was maintained for the duration of the reaction. 
Detergents  and  their  concentrations  were  selected  based  on  previous  studies  that 
tested the compatibility of detergents with cell-free expression systems
54. Digitonin was 
purchased from Invitrogen, and DDM, Triton X-100, Brij-58, Brij-S20 and Brij-98 were 
purchased from Sigma. For reactions performed in the presence of liposomes, asolectin 
vesicles were added to the reaction mixture at concentrations ranging from 0.2 to 1 
mg/ml. 
 
Purification of MCU using nickel chromatography 
Spin columns containing nickel nitrilotriacetic acid (NTA) resin were purchased 
from  Qiagen  (31014)  and  used  to  purify  soluble  MCU  from  cell-free  reactions 
supplemented with 1% digitonin or 0.2% Brij-98. The protocol outlined in the Qiagen 
manual for protein purification under native conditions from E. coli lysates was followed. 
Detergent concentrations used in the cell free reaction were maintained throughout the 
purification process. The flow-through, wash and elution fractions were collected, and 
protein was precipitated with acetone for SDS-PAGE and western blot analysis. 
 
Analysis of cell-free MCU produced in the presence of liposomes 
Following  the  cell-free  reaction,  vesicles  were  purified  by  sucrose  gradient 
centrifugation as previously described
55. The reaction mixture was diluted with 25 mM 
HEPES-KOH to a final volume of 300 µl and a final w/w sucrose concentration of 60%. 
This was placed at the bottom of a tube and a gradient was created using 56, 53, 50,   40!
47,  44,  41,  38  and  36%  sucrose  solutions.  The  tubes  were  centrifuged  for  40h  at 
280,000g at 10°C. Fractions were collected from the top, and protein from each fraction 
was precipitated using 10% trichloroacetic acid (TCA) for SDS-PAGE and western blot 
analysis.  To  assess  protein  insertion  using  a  complementary  method,  vesicles  were 
treated with urea following the cell free reaction
55. This was achieved by recovering 
vesicles from the cell-free reaction by centrifugation at 24,000g for 10 minutes. The 
pellet was then resuspended in 200 µl of 20 mM Tris (pH 7.0) containing 4M urea. The 
vesicles were incubated for 30 minutes at room temperature. Subsequently, they were 
diluted 2x with 20 mM Tris containing 250 mM NaCl. The vesicles were then subjected 
to a high-speed spin at 285,000g for 30 minutes at 18 °C. The soluble and insoluble 
fractions were kept for SDS-PAGE and western blot analysis. 
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RESULTS 
Calcium transport can be measured in asolectin vesicles loaded with CG5N 
In this assay, lipid vesicles are loaded with a calcium indicator that fluoresces in 
the presence of calcium. A low affinity indicator was selected to reduce background 
signal due to low levels of calcium present in buffer and to ensure a robust response to 
calcium as it is transported into lipid vesicles. Calcium Green-5N (CG5N) has a KD of 
~14 µM (Invitrogen product manual), which is at least one order of magnitude greater 
than the majority of calcium indicators currently available. Therefore, it was chosen as 
the low-affinity indicator for this assay.! 
To establish a positive control for calcium transport, A23187, a bacterial calcium 
ion-carrier, was added to liposomes containing CG5N in the absence of calcium. Next, 
calcium  was  rapidly  mixed  with  vesicles  and  fluorescence  was  monitored  using  a 
stopped flow spectrophotometer (Figure 1a). In the presence of A23187, robust calcium 
transport was detected in a dose-dependent manner that exceeded the slow increase in 
fluorescence  due  to  calcium  permeation  through  the  vesicle  membrane  (Figure  1b). 
This proof-of principle experiment demonstrated that the vesicles were intact and that 
CG5N was a suitable indicator for measuring calcium transport in vesicles.! 
This assay was developed using phosphatidylcholine (22:1) (Avanti Polar Lipids), 
but once validated, was replaced with asolectin, a natural soybean extract containing a 
mixture of lipids, because numerous mitochondrial transporters have been reconstituted 
using this lipid, including LETM1, a Ca2+:2H antiporter located on the inner membrane 
that  contributes  to  calcium  efflux  from  mitochondria
49.  Initially,  the  asolectin  vesicles 
were  tested  using  stopped  flow  spectrophotometry.  Similar  to  liposomes  containing 
phosphatidylcholine, these vesicles demonstrated a robust response to A23187.   42!
 
Figure  1.  Calcium  transport  in  DC22:1PC  liposomes  loaded  with  CG5N.  (a)  Schematic 
overview  of t h e   transport  assay  in  a s t o p p e d  f l o w  s p e c t r o p h o t o m e t e r .  (b)  Dose-dependent 
calcium transport is detected in response to A23187. 
 
After transport was validated in asolectin vesicles, the assay was established 
using a standard spectrophotometer. In this configuration, the vesicles were placed into 
a quartz cuvette and the excitation and emission wavelengths were set to match the 
spectral characteristics of CG5N, which undergoes an increase in emission intensity 
after binding micromolar amounts of calcium. In this assay, fluorescence was measured 
as a function of time, and A23187, calcium or EGTA was added at different time points   43!
using a syringe. Although this approach lacks the kinetic resolution of the stopped flow 
method, it is sufficient to observe whether transport has occurred. In the future, this 
could be adapted to a plate reader format for high-throughput compound screening in 
which  injectors  coordinate  the  administration  of  calcium,  EGTA  and  A23187  as  a 
positive control.! 
In the initial set of experiments, the response of vesicles to A23187 was tested to 
find  the  minimal  amount  of  vesicles  needed  to  see  a  robust  response.  To  start, 
liposomes were diluted to 2 mg/ml, and calcium (10mM) or EGTA (1mM) was added 
before a spike of 5 µM A23187 was administered (Figure 2 a, b). As expected, influx 
was  observed  with  calcium,  and  efflux  was  seen  with  EGTA,  which  established  a 
concentration  gradient  across  the  liposome  by  chelating  residual  calcium  present 
outside of the vesicles. Identical results were obtained if calcium or EGTA was added 
after the ionophore. To determine the minimal amount of liposomes required for the 
assay, serial dilutions were performed, which revealed that a robust response could be 
seen with 0.15 mg/ml of asolectin vesicles.  
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Figure 2. Calcium transport in asolectin liposomes. Liposomes were diluted to 2mg/ml and 
calcium transport was measured using a standard spectrophotometer. 
 
Interestingly,  the  response  to  A23187  was  substantially  greater  following  the 
addition of EGTA compared to calcium. The signal decreased by approximately 5.5 fold 
after EGTA was added, whereas it increased by 0.35 fold following a spike of calcium. 
This was unexpected and may represent residual calcium in the buffer or contamination 
of  asolectin  lipid  with  high  amounts  of  calcium.  The  results  of  these  experiments 
indicate that an efflux assay in which EGTA is added to the buffer outside the liposomes 
may be preferable due to the substantial signal change in response to calcium efflux. In 
this configuration, if a transporter or channel is present, residual calcium within vesicles 
can exit due to a concentration gradient established by strong calcium chelator present 
outside the liposomes. Assuming unbiased insertion of protein into vesicles, an efflux 
assay  should  be  equivalent  to  an  influx  assay  for  evaluating  transport  across 
proteoliposomes.   45!
In July of 2011, I traveled to the laboratory of Dr. Andersen where I worked with 
post-doctoral fellow, Dr. Helgi Ingólfsson, to further optimize the stopped flow assay. 
Since the baseline signal of asolectin vesicles was unexpectedly high in my previous set 
of  experiments  performed  on  a  standard  spectrophotometer,  I  was  interested  in 
determining the maximum and minimum CG5N signal relative to baseline in the vesicles 
I prepared in this laboratory. To measure the maximum and minimum CG5N signal, the 
vesicles were lysed by treating them with 0.1% Triton or subjecting them to multiple 
freeze  thaw  cycles.  This  liberated  the  vesicle-encapsulated  fluorophore,  which  was 
rapidly m i x e d  with  10  mM  CaCl2  or  1  mM  EGTA  to  determine  the  maximum  and 
minimum CG5N signal (Figure 3 a, b). 
Although these complementary methods gave consistent values for the minimum 
and  maximum  fluorescence,  there  was  an  unexpectedly  slow  response  of  liberated 
CG5N to calcium (Figure 3 a, b). This delayed response was also observed if CG5N 
was diluted in buffer, and calcium or EGTA was added. Since the kinetic rate constant 
for association of CG5N with calcium is on the order of microseconds, calcium should 
be able to bind and dissociate from CG5N within the dead time of the stopped flow 
machine,  which  is  approximately  2  milliseconds
56.  This  was  an  essential  issue  to 
resolve  because  in  its  current  form,  the  assay  did  not  distinguish  free  CG5N  from 
transport into or out of liposomes. 
Although puzzling, it was reasoned that this may reflect a contaminant metal in 
the fluorophore or in our buffer. For example, if CG5N binds to other metals with a low-
affinity, their dissociation may be rate limiting, rather than calcium binding. To address 
this possibility, we decided to test whether the presence of metal chelators (e.g. EGTA) 
in our buffer can “strip” the fluorophore of contaminants to resolve this kinetic issue.    46!
 
Figure  3.  Free  CG5N  demonstrates  slow  response  kinetics  to  calcium  and  EGTA.  (a) 
Vesicles were lysed using 0.1% Triton and rapidly mixed with calcium, buffer or EGTA. (b) 
Vesicles  were  subjected  to  five  freeze-thaw  cycles  to  liberate  encapsulated  CG5N.  Lysed 
vesicle were rapidly mixed with calcium, buffer or EGTA. 
 
Therefore, our goal was to make vesicles in the presence of EGTA. We wanted 
to avoid adding excess EGTA because this could adversely affect vesicle integrity or 
chelate calcium that is transported across liposomes, blocking our ability to observe 
calcium transport. Thus, vesicles were lysed and an EGTA titration was performed to   47!
find the minimum amount needed to “kill” the CG5N signal due to residual calcium, with 
the hope that this would also resolve the delayed kinetics observed when CG5N was 
released from lysed vesicles. This experiment revealed that 50 µM EGTA was sufficient 
to minimize the CG5N signal.  
To test whether the presence of EGTA within vesicles could prevent the delayed 
response of lysed vesicles to calcium, asolectin lipid was rehydrated in buffer containing 
50 µM EGTA, which was maintained throughout the entire vesicle preparation, including 
the freeze thaw cycles, extrusion and elution. Remarkably, this strategy was effective in 
resolving the delayed kinetics observed in the setting of lysed vesicles. When vesicles 
were lysed with 0.1% Triton (Figure 4a), the addition of calcium resulted in a stepwise 
jump in the fluorescent signal rather than a slower rise resembling true transport, as 
seen  with  the  addition  of  A23187  (Figure  4b).  Furthermore,  the  addition  of  EGTA 
reduced the baseline signal to its minimum value. This resulted in a ten-fold change in 
fluorescence following the addition of calcium (Figure 4b), which significantly improved 
the signal-to-noise ratio of the influx assay. Thus, the addition of EGTA to the vesicle 
preparation  resolved  multiple  technical  issues,  including  the  inability  to  distinguish 
between  lysed  vesicles  and  rapid  channel-mediated  transport,  and  the  small  signal 
change seen in response to calcium influx.! 
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Figure 4. Vesicles prepared with 50 µM EGTA have normal response kinetics to calcium 
and EGTA. (a) Vesicles were lysed using 0.1% Triton and rapidly mixed with calcium, buffer or 
EGTA. (b) Vesicles pre-mixed with A23187 were rapidly mixed with calcium, buffer or EGTA. 
 
MCU can be produced in a cell-free expression system 
 In  parallel  to  a  collaborative  effort  in  developing  a  liposome-based  calcium 
transport  assay,  I  also  pursued  a  protocol  for  generating  soluble  MCU  for 
proteoliposome  reconstitution.  Our  first  strategy  was  to  express  MCU  in  a  cell-free   49!
system  using  a  commercially  available  kit  for  in  vitro  translation  (IVT).  Cell-free 
expression of membrane proteins for functional and structural studies represents an 
attractive  alternative  to  recombinant  expression  in  bacterial  or  yeast  systems,  which 
suffer from disadvantages such as protein aggregation, toxic effects on the host, and 
difficulty recovering intact protein from host cell membranes
57,58. Traditionally, cell free 
reactions can be performed using bacterial or eukaryotic extracts to produce membrane 
proteins as a precipitate (P-CF) or in soluble form in the presence of detergent (D-CF) 
or lipid (L-CF)
58. 
MCU  was  cloned  into  a  prokaryotic  expression  vector  (pEXP5-CT/TOPO) 
containing  a  C-terminal  6xHis  tag,  which  can  be  used  for  western  blot  analysis  of 
protein yield and affinity purification. To generate protein, a commercially available kit 
from Invitrogen was ordered that utilizes E. coli extract and is optimized for expression 
of recombinant membrane proteins in microgram to milligram quantities. The kit also 
includes bacteriorhodopsin (bR) in pEXP5-CT/TOPO as a positive control for protein 
expression.  
In  initial  experiments,  MCU  was  partially  insoluble  following  the  CF  reaction 
(Figure 5). Previous experiments have demonstrated that proteins produced in soluble 
form have a higher probability of being functional. Therefore, I decided to screen a set 
of detergents that could be added to the cell-free reaction to shift production of MCU 
into the soluble fraction.! 
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Figure 5. MCU is partially insoluble following expression in a cell-free system. Following 
IVT, the soluble (S) and insoluble (P) fractions were separated by centrifugation and analyzed 
by SDS-PAGE and western blot. 
 
A detergent screen identifies a set of detergents compatible with cell-free expression of 
soluble MCU 
A  list  of  detergents  was  generated  based  on  previous  studies  that  tested 
detergents for their compatibility with cell-free systems
54. Among the detergents tested 
include digitonin, DDM, Triton X-100, Brij-58, Brij-S20 and Brij-98. Each was tested at 
two  concentrations  based  on  values  reported  in  previous  studies  in  which  cell-free 
reactions were supplemented with detergent. To assess the efficacy of each detergent, 
total protein production was compared to a reaction without detergent to ensure that the 
presence of the detergent did not adversely affect the reaction efficiency. In addition, 
the soluble and insoluble fractions were separated after the reaction by centrifugation 
and analyzed using SDS-PAGE and western blot. Figure 6 shows an example of this 
analysis in which three detergents were tested. As can be seen on the gel, 1% DDM 
and 1.5% Brij-58 result in a substantial amount of MCU in the insoluble fraction (Figure 
6a). This is in contrast to 1% digitonin, which results in nearly 100% of MCU in the 
soluble fraction (Figure 6a). The results of the screen revealed that 1% digitonin and 
0.2% Brij-98 are detergents compatible with CF production of soluble MICU3 (Figure 
6b).   51!
 
Figure 6. A screen identifies two detergents that enable cell-free expression of soluble 
MCU. (a) Results are shown from a subset of the detergents tested. Total (T), soluble (S) and 
insoluble (P) fractions are shown for each detergent. For reactions supplemented with 1% DDM 
and  1.5%  Brig-58  (B-58),  a  fraction  of  MCU  is  insoluble.  This  is  in  contrast  to  reactions 
containing 1% digitonin (Dig) in which MCU is fully soluble. (b) Cell-free reactions supplemented 
with either 1% digitonin (Dig) or 0.2% Brij-98 (B-98) produce soluble MCU. 
 
Purification of soluble MCU using Ni-NTA spin columns 
Since the soluble fraction was contaminated by many proteins from the E. coli lysate, 
we were interested in developing a purification scheme prior to incorporating soluble 
MCU  into  lipid  vesicles.  We  decided  to  use  nickel  affinity  chromatography  because 
MCU was synthesized with a C-terminal 6xHis tag. To choose the appropriate affinity 
system for purification, I needed an estimate of how much soluble MCU was produced 
by the cell-free system. Therefore, I performed serial dilutions of the soluble fraction and 
ran these on a gel with 5 6xHis-tagged protein standards with known concentrations. 
This enabled me to estimate the amount of soluble MCU generated by one 100 µl cell-
free reaction, which was between 10-50 µg. Based on this, I chose to use Ni-NTA spin 
columns  for  affinity  purification.  Maintaining  the  detergent  concentration  through  the 
entire  purification,  flow-through,  wash  and  elution  fractions  were  obtained.  I  took  a 
sample from each fraction and precipitated the protein for SDS-PAGE and western blot   52!
analysis. In the case of both detergents, the majority of the protein appeared in the 
elution fractions (Figure 7). Unfortunately, on a gel stained with coomassie brilliant blue 
R-250, soluble MCU was not the dominant band in the elution fraction, indicating the 
need for further purification or modifications to the cell-free reaction to boost yield. 
 
 
Figure  7. P u r i f i c a t i o n  o f  s o l u b l e  M C U  u s i n g  n i c k e l  a f f i n i t y  c h r o m a t o g r a p h y .   C e l l -free 
reactions supplemented with 1% digitonin (Dig) or 0.2% Brij-98 (B-98) were processed using Ni-
NTA spin columns. The flow-through (FT), wash (W1 and W2) and elution (E1 and E2) fractions 
were collected and analyzed using SDS-PAGE and western blot. 
 
MCU  is  associated  with  liposomes  following  cell-free  expression  supplemented  with 
liposomes 
Since certain proteins are able to insert directly into liposomes during IVT, I also 
performed cell-free expression in the presence of pre-formed liposomes
55,59,60. Based 
on previous studies
55,59,60, I tested several liposome concentrations in the range of 0.2-2 
mg/ml.  After  the  reaction,  I  used  two  approaches  to  assess  whether  protein  was 
associated with the vesicles. The first was sucrose gradient centrifugation, which was 
used to separate liposomes and any associated proteins from the rest of the cell-free 
extract
55. This is a form of density gradient centrifugation, and it is an effective way to   53!
separate liposomes from the rest of the reaction contents because are less dense and 
consequently float to the top. The cell-free reaction was diluted and a discontinuous 
sucrose gradient was layered on top of it. After spinning the tube at high speed for 
several hours, fractions were collected and analyzed by SDS-PAGE and western blot. 
In  the  reaction  containing  no  liposomes,  MCU  was  located  in  the  bottom  fractions 
(Figure 8). However, in the reaction containing 2 mg/ml of liposomes, the protein was 
found in middle and top fractions, indicating partial localization with liposomes (Figure 
8).  
To further assess whether MCU was associated with liposomes, I isolated the 
vesicles  after  the  reaction  using  centrifugation,  and  resuspended  them  in  urea  to 
denature  and  remove  loosely  associated  proteins
55.  Subsequently,  the  reaction  was 
diluted and spun at high speed to pellet the liposomes. The supernatant (S2) and pellet 
(P)  were  saved  for  SDS-PAGE  and  western  blot  analysis,  as  was  the  supernatant 
resulting from the first centrifugation step in which the vesicles were isolated from the 
reaction mixture (S1). Interestingly, there was an enrichment of MCU in the pellet (P), 
suggesting  that  a  substantial  amount  of  MCU  was  associated  or  inserted  into  the 
liposomes. This was not seen when a control protein, CALM3, was taken through the 
cell-free reaction and urea treatment. In this case, CALM3 localized exclusively to the 
first supernatant (S1). Taken together, these two approaches provide evidence that a 
subset  of  MCU  is  associated  or  incorporated  into  liposomes.  Unfortunately,  when 
transport  was  tested  in  these  vesicles,  no  increased  calcium  flux  relative  to  control 
liposomes was observed. This could be due to a variety of factors, including insufficient 
yield, failure to insert or non-functional protein. 
   54!
 
 
 
 
 
 
Figure 8. Sucrose gradient centrifugation reveals that a subset of MCU is associated with 
liposomes following IVT. (a) Schematic diagram depicting sucrose gradient centrifugation. (b) 
Following an extended high-speed spin, fractions were collected from the top of the tube and 
analyzed by SDS-PAGE and western blot using an anti-His antibody. In reactions supplemented 
with 2 mg/ml liposomes, there was a shift in the distribution of MCU toward the top, suggesting 
that some of the protein is associated with or inserted into liposomes. 
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Figure  9.  MCU  is  associated  with  liposomes  treated  with  4M  urea  following  IVT.  (a) 
Schematic diagram depicting the isolation of liposomes for urea treatment. (b) A subset of MCU 
was in the insoluble fraction (P) following urea treatment. A control protein (CALM3) was found 
exclusively in the soluble fraction isolated before urea treatment (S1). 
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DISCUSSION 
The development of a reconstitution system is an important next step for studying 
the biophysical properties of MCU and devising a platform for in vitro identification of 
compounds that target the mitochondrial calcium uniporter. In this chapter, I describe 
my contribution to the development of a liposome-based assay for calcium transport. I 
also  discuss  the  application  of  a  cell-free  expression  system  for  proteoliposome 
reconstitution  of  MCU.  In  the  results  section,  I  highlight  two  strategies  for  achieving 
reconstitution,  which  include  production  of  detergent-solubilized  protein  and  direct 
insertion of MCU into pre-formed liposomes. These approaches were devised based on 
previous studies in which cell-free expression systems were used to generate functional 
proteoliposomes. 
At  present,  we  have  validated  our  liposome  transport  assay  using  A23187,  a 
bacterial  ionophore  that  binds  calcium  and  facilitates  transport  across  lipid 
membranes
61. The addition of EGTA to the vesicle preparation has resolved two issues, 
including  a  delayed  response  of  our  fluorescent  indicator  to  calcium  and  the  high 
baseline fluorescent signal seen in asolectin vesicles due to residual calcium present in 
the buffer or lipid. As a result, we now have a sensitive influx assay that undergoes a 
several-fold change in signal intensity following calcium influx and distinguishes rapid 
channel-mediated transport from unstable vesicles that have release their encapsulated 
CG5N.  
To  generate  protein  for  proteoliposomes,  we  decided  to  use  a  cell-free 
expression system rather than attempting recombinant expression in bacterial or yeast 
systems.  The  observation  that  proteins  produced  in  soluble  form  have  a  higher 
probability  of  being  functional  motivated  us  to  pursue  this  strategy  because  soluble   57!
membrane  proteins  can  be  directly  recovered  from  cell-free  systems,  particularly  if 
reactions  are  supplemented  with  detergent  or  lipid
58,62.  This  is  in  contrast  to 
recombinant  expression  in  bacteria  or  yeast  where  the  vast  majority  of  membrane 
proteins are recovered from insoluble inclusion bodies using detergents. Therefore, in 
order  to  avoid  an  insoluble  intermediate,  we  conducted  cell-free  reactions  in  the 
presence of IVT-compatible detergents or pre-formed liposomes. 
Our  results  revealed  that  soluble  MCU  could  be  generated  by  supplementing 
cell-free reactions with 1% digitonin or 0.2% Brij-98. Following the reaction, MCU was 
purified from the reaction mixture using Ni-NTA affinity chromatography. Although the 
majority of MCU appeared in the elution fraction, several other proteins were present in 
this fraction, as well. Furthermore, MCU was present in low abundance relative to these 
contaminant proteins, indicating the need for further optimization to boost protein yield. 
This may involve increasing reaction time or experimenting with different formulations, 
such as wheat germ extract. We will also explore the possibility of switching from a one-
compartment  batch  reaction t o  a  continuous-exchange  system,  which  features  two 
chambers separated by a semi-permeable membrane that allows for exchange of waste 
products and fresh, low-molecular weight substrates required for IVT, including amino 
acids and ATP
58. Although more complex, continuous-exchange systems may represent 
a better alternative for producing high amounts of soluble protein. 
In  cell-free  reactions  supplemented  with  liposomes,  a  subset  of  MCU  was 
associated  with  vesicles  following  cell-free  expression.  This  was  shown  by  two 
complementary  approaches,  including  sucrose  gradient  centrifugation  and  treating 
liposomes with urea. Although more experiments are required to distinguish between 
strong association and insertion of MCU, and to assess whether contaminant proteins   58!
are inserted into liposomes, these preliminary results indicate that direct insertion of 
MCU  into  pre-formed  liposomes  during  IVT  may  be  a  viable  strategy  for  generating 
proteoliposomes. As demonstrated by their response to A23187, the majority of vesicles 
were intact following cell-free expression. Unfortunately, we did not observe calcium 
transport in liposomes isolated from cell-free reactions in which MCU was produced, 
indicating reconstitution was not successful. This could be due to a variety of factors, 
including insufficient yield, failure to insert or non-functional protein. 
  Moving  forward,  we  will  focus  on  increasing  protein  yield  in  our  cell-free 
expression  system.  This  will  provide  more  starting  material  for  Ni-NTA  affinity 
purification and allow us to explore complementary purification methods such as gel 
filtration. At the same time, it will increase the amount of MCU available for insertion into 
liposomes, which may enable us to detect transport in proteoliposomes isolated directly 
from the cell-free reaction. If we are unable to boost MCU production using cell-free 
expression, we will explore other systems, including recombinant expression in bacteria 
and yeast. 
  Once  we  generate  a  sufficient  amount  of  soluble  MCU,  we  will  attempt  to 
incorporate  it  into  liposomes  using  a  detergent-mediated  strategy
63.  This  approach 
involves  partially  solubilizing  liposomes  so  that  they  are  accessible  to  interact  with 
soluble  MCU.  Following  an  incubation  period,  detergent  will  be  removed  using 
hydrophobic  beads  to  induce  the  formation  of  vesicles  containing  lipid  and  protein, 
which can be monitored by an increase in side-scatter.  
Naturally, this will present numerous challenges, including choosing a detergent, 
optimizing the protein-to-lipid ratio and finding a concentration of hydrophobic beads 
that  removes  detergent  but  leaves  liposomes  intact.  In  preliminary  experiments,  we   59!
found  that  Triton  X-100  solubilized  liposomes  and  that  it  could  be  removed  using 
hydrophobic beads to induce vesicle reformation. This suggests that Triton X-100 may 
be  an  attractive  detergent  choice  for  reconstitution,  although  its  compatibility  with 
soluble MCU needs to be tested in an experimental setting.  
The prospect of reconstituting MCU is exciting. If we are able to demonstrate 
calcium transport activity, we will test whether it reflects previously reported biophysical 
and pharmacological properties of the uniporter, including high selectivity for calcium, 
sodium transport in divalent-free conditions and inhibition by Ru-360
22. This system will 
enable us to further explore the biology of MCU by testing the effect of mutants on 
channel  conductance,  selectivity  and  response  to  Ru-360,  which  may  motivate 
additional  in  vivo  experiments.  Furthermore,  it  will  provide  a  platform  for  an  in  vitro 
chemical screen to identify compounds that alter MCU activity, which may represent 
novel therapies for human disease. 
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Conclusion 
The  recent  molecular  characterization  of  the  mitochondrial  calcium  uniporter 
marks the end of a fifty search and opens a new era in molecular mitochondrial calcium 
biology. Now, there is a rich set of genetic approaches that can directly probe the role of 
mitochondrial  calcium  transport  in  cellular  physiology  and  disease.  In  addition,  the 
identification  of  MCU  and  MICU1  enables  a  diverse  collection  of  biochemical  and 
computational  approaches  to  identify  proteins  that  functionally  interact  with  known 
components  of  the  uniporter.  Together,  these  studies  will  clarify  the  longstanding 
association of uniporter activity with cellular metabolism and apoptosis, as well as its 
relationship to the pathogenesis of numerous diseases, including neurodegeneration, 
cancer and ischemic injury.  
In this thesis, I explore two areas within the growing field of mitochondrial calcium 
biology. First, I discuss the identification of MICU2, a previously uncharacterized protein 
important for mitochondrial calcium uptake. In this study, I define a family of paralogous 
proteins that include MICU1, MICU2 and MICU3, which likely arose by gene duplication 
event prior to vertebrate evolution, and present data that implicates both MICU1 and 
MICU2 in establishing the capacity of mitochondria to buffer calcium. Although more 
experiments are needed, our results suggest that MICU1 and MICU2 interact with MCU 
in the same cell type and that they have overlapping roles in mediating mitochondrial 
calcium  buffering.  Moving  forward,  it  will  be  important  to  understand  how  these 
paralogous proteins partner with MCU to achieve high-capacity mitochondrial calcium 
uptake. 
In a second body of work, I discuss my work in developing an in vitro system to 
characterize  MCU,  the  pore-forming  subunit  of  the  mitochondrial  calcium  uniporter.   61!
Although MCU demonstrated channel-activity in planar lipid bilayers, there are many 
unanswered questions regarding the biophysical properties of the uniporter, including its 
selectivity to other ions, allosteric activation by calcium and pharmacological response 
to  a  variety  of  compounds.  In  addition,  it  is  not  clear  which  residues  contribute  to 
calcium transport, the selectivity filter and response to Ru-360. Reconstitution of MCU in 
proteoliposomes  will  enable  us  to  systematically  address  these  questions  using 
fluorescence  spectroscopy  and  electrophysiology,  which  will  further  motivate  in  vivo 
studies. A scalable transport assay also opens up the possibility of performing an in 
vitro drug screen to identify compounds that target the uniporter, which may represent 
novel therapeutics for human disease. 
As we learn more about the biology of mitochondrial calcium transport, we can 
design  experiments  to  elucidate  the  role  of  this  conserved  pathway  in  cellular 
physiology and the pathogenesis of human disease. Although mutations in components 
of  the  respiratory  chain  cause  a  devastating  class  of  disorders  characterized  by 
endocrine,  neurological  and  muscle  myopathies,  it  is  unknown  whether  mutations  in 
components of the uniporter give rise to inherited disorders. In addition, the association 
of defects in mitochondrial calcium transport with common pathologies such as cancer, 
neurodegeneration and ischemic injury has yet to be definitively proven. It is my hope 
that  the  work  presented  in  this  thesis  will  contribute  to  a  deeper  understanding  of 
mitochondrial  calcium  biology,  which  will  inform  future  studies  exploring  the  role  of 
mitochondrial calcium transport in human disease. 
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Summary 
Calcium signaling orchestrates a diverse set of cellular events, including muscle 
contraction,  neurotransmission  and  growth
64.  The  specific  role  of  mitochondria i n  
regulating cytosolic calcium is unclear at present, but there is evidence that they may 
play a critical role in decoding cytosolic calcium signals to initiate a cellular response
8. 
The ability of mitochondria to transport large amounts of calcium was documented over 
fifty years ago
14,15, but it was only recently that the first molecular components of the 
uniporter  were  identified
25,26,39.  These  include  MICU1,  an  EF-hand  protein  that  may 
function as a regulatory component by sensing calcium, and MCU, the channel-forming 
subunit  of  the  uniporter.  Key  to  solving  this  mystery  was  an  approach  inspired  by 
comparative physiology and integrative genomics.  
Here,  I  discuss  the  identification  of  a  previously  uncharacterized  regulator  of 
mitochondrial calcium uptake that shares a common ancestor with MICU1.  EFHA1, 
which we rename MICU2, physically interacts with MICU1 and MCU and undergoes 
coregulation with MICU1 at a protein level. Our physiology data suggest that MICU1 
and MICU2 have independent contributions to establishing the capacity of mouse liver 
mitochondria to buffer calcium. In HeLa cells, MICU2 can rescue a defect in calcium 
uptake  in  the  setting  of  reduced  MICU1,  whereas  MCU  cannot.  This  suggests  that 
MICU2 either stabilizes low levels of MICU1 or directly compensates for MICU1 loss as 
a functional paralog. Futures studies will elucidate how these proteins function as a 
complex to facilitate high-capacity calcium transport. 
In addition, I describe my contribution to three components of an in vitro system 
for  proteoliposome  reconstitution  of  MCU,  the  channel-forming  subunit  of  the 
mitochondrial  calcium  uniporter.  These  include  developing  an  assay  for  transport,   63!
expressing  soluble  protein  and  incorporating  it  into  vesicles.  At  present,  we  have 
established  a  robust  transport  assay  and  are  currently  exploring  ways  to  generate 
soluble protein for incorporation into lipid vesicles. The development of a reconstitution 
system will enable detailed biophysical analysis of the uniporter, which will complement 
ongoing in vivo studies. Furthermore, it may provide a platform for in vitro identification 
of compounds that modulate mitochondrial calcium transport. 
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